Funding Agency Stop Work Orders: Sample IRB Guidelines for Investigators. View Now
Expert research ethics and compliance support, staffing and advisory services since 2009.
The HRP Group Contact Us

Latest from HRP Consulting Group

Regulatory updates, guidance summaries and news from the HRP team.

Resources

Working with Vulnerable Populations

This presentation reviews what "vulnerability" means when conducting human-subjects research. "Vulnerability" should be understood broadly and contextually — beyond just legally defined groups — and researchers must proactively identify and mitigate a variety of risks (e.g. power imbalances, coercion, confidentiality,…

Read more →
Resources

Summary DOJ NIH Rules on Sensitive Data Access

The attached document provides a summary of the new rules from the U.S. Department of Justice (DOJ) and National Institutes of Health (NIH) that tighten controls on access to U.S. “bulk sensitive personal data” and government-related data — forbidding or…

Read more →
Resources

Comparison of FDA Regulations (Current and Proposed) & Common Rule

This document provides a detailed side-by-side comparison of the regulations under Common Rule and current (and proposed) U.S. Food and Drug Administration (FDA) regulations (21 CFR 50/56 etc.), showing how FDA’s human-subjects-research and IRB requirements could be harmonized — or…

Read more →
Resources

Update – Clinical Decision Support Software Final Guidance

A one page summary to clarify guidance on determining when CDS software is excluded from the definition of a “medical device” under section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Only software functions that meet all four specified…

Read more →
Resources

FDA Proposed Rule: Investigational New Drug Applications: Exemptions for Clinical Investigations to Evaluate a Drug Use of a Product Lawfully Marketed as a Conventional Food, Dietary Supplement or Cosmetic

The purpose of this overview is to explain a proposed U.S. Food and Drug Administration (FDA) rule that would create formal exemptions from investigational new drug (IND) requirements for certain clinical studies of products lawfully marketed as conventional foods, dietary…

Read more →